Suppr超能文献

接受阿司匹林治疗的患者发生缺血性脑卒中。

Ischemic stroke in patients receiving aspirin.

机构信息

Institute for Neurological Research, FLENI, Buenos Aires, Argentina.

出版信息

J Stroke Cerebrovasc Dis. 2012 Nov;21(8):868-72. doi: 10.1016/j.jstrokecerebrovasdis.2011.05.009. Epub 2011 Jun 23.

Abstract

BACKGROUND

The widespread use of aspirin-driven vascular prevention strategies does not impede the occurrence of first and recurrent ischemic strokes in numerous subjects. It is not clear what factors are associated with aspirin failure beyond the functional diagnosis of aspirin resistance in selected subjects. Current management guidelines provide little or no recommendations on the proper strategy for subjects who had a stroke while receiving aspirin. We assessed clinical features of subjects who had a first or recurrent stroke while taking aspirin.

METHODS

We studied demographic characteristics, vascular risk factors, stroke subtypes, and concomitant medication use in subjects with first or recurrent ischemic strokes. Patients receiving antiplatelet medications other than aspirin and/or oral anticoagulants were excluded from this analysis.

RESULTS

Seven hundred and nine patients with first (n = 552) or recurrent (n = 157) ischemic stroke were evaluated. Aspirin was being taken by 29% of first and 48% of recurrent stroke subjects. There was a higher prevalence of hypertension, hypercholesterolemia, and smoking in aspirin users with first and recurrent stroke (P < .05). Diabetes and coronary artery disease were more frequent in aspirin users with first ischemic strokes (P < .003), but not in those who had recurrent ischemic strokes. Aspirin users were more likely to be also receiving statins and antihypertensive drugs (P < .001).

CONCLUSIONS

Aspirin failure in ischemic stroke prevention may exceed functional resistance to aspirin and could be associated with a higher prevalence of lacunar stroke, comorbidities, and/or adverse interactions with other drugs. These patients may require a different approach regarding prevention strategies.

摘要

背景

尽管广泛应用阿司匹林驱动的血管预防策略,但在许多患者中,首次和复发性缺血性卒中的发生仍无法避免。除了在特定患者中对阿司匹林抵抗进行功能诊断外,尚不清楚阿司匹林失败与哪些因素有关。现行管理指南几乎没有或根本没有针对正在服用阿司匹林的患者发生卒中时的适当策略的建议。我们评估了正在服用阿司匹林的患者首次或复发性卒中的临床特征。

方法

我们研究了首次或复发性缺血性卒中患者的人口统计学特征、血管危险因素、卒中亚型和同时使用的药物。本分析排除了正在服用除阿司匹林以外的抗血小板药物和/或口服抗凝剂的患者。

结果

共评估了 709 例首次(n=552)或复发性(n=157)缺血性卒中患者。29%的首次卒中患者和 48%的复发性卒中患者正在服用阿司匹林。服用阿司匹林的首次和复发性卒中患者中高血压、高胆固醇血症和吸烟的患病率更高(P<.05)。首次缺血性卒中患者中糖尿病和冠心病更为常见(P<.003),而复发性缺血性卒中患者中则不然。服用阿司匹林的患者更有可能同时服用他汀类药物和降压药(P<.001)。

结论

在缺血性卒中预防中,阿司匹林失败可能超过阿司匹林的功能抵抗,并且可能与腔隙性卒中、合并症和/或与其他药物的不良相互作用的更高患病率有关。这些患者可能需要针对预防策略采取不同的方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验